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Abstract
Background: Renal cell carcinoma (RCC) is histopathologically heterogeneous with clear cell and
papillary the most common subtypes. The most frequent molecular abnormality in clear cell RCC
is VHL inactivation but promoter methylation of tumour suppressor genes is common in both
subtypes of RCC. To investigate whether RCC CpG methylation status was influenced by
histopathology and VHL status we performed high-throughput epigenetic profiling using the Illumina
Goldengate Methylation Array in 62 RCC (29 RCC from von Hippel-Lindau (VHL) disease patients,
20 sporadic clear cell RCC with wild type VHL and 13 sporadic papillary RCC).
Results: 43 genes were methylated in >20% of primary RCC (range 20–45%) and most (37/43) of
these had not been reported previously to be methylated in RCC. The distribution of the number
of methylated CpGs in individual tumours differed from the expected Poisson distribution (p <
0.00001; log-likelihood G test) suggesting that a subset of RCC displayed a CpG Island Methylator
Phenotype. Comparison of RCC subtypes revealed that, on average, tumour specific CpG
methylation was most prevalent in papillary RCC and least in VHL RCC. Many of the genes
preferentially methylated in pRCC were linked to TGFβ or ERK/Akt signalling.
Conclusion: These findings demonstrate differing patterns of tumour-specific CpG methylation in
VHL and non VHL clear cell RCC and papillary RCC, and identify multiple novel potential CpG
methylation biomarkers for RCC.
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Renal cell carcinoma (RCC) accounts for 2–3% of all can-
cers, and most kidney cancers arise from the renal tubule
epithelium. The most common types of RCC, accounting
for ~90% of tumours, are conventional (clear cell) renal
cell carcinoma (cRCC) and papillary (pRCC). Investiga-
tions of rare inherited forms of RCC have provided
insights into the molecular pathogenesis of both familial
and sporadic RCC. Thus the identification of the gene for
von Hippel-Lindau (VHL) disease (a dominantly inher-
ited familial cancer syndrome characterised by the devel-
opment of retinal and central nervous system
haemangioblastomas, cRCC, pancreatic lesions and phae-
ochromocytoma) led to the recognition that the most fre-
quent genetic event in the evolution of sporadic cRCC is
somatic inactivation of the VHL tumour suppressor gene
(TSG) [1-4]. However, VHL inactivation is not a feature of
pRCC.
Epigenetic inactivation of TSGs by methylation of pro-
moter region CpG dinucleotides has been frequently
implicated in the pathogenesis of human cancers includ-
ing RCC. Thus epigenetic silencing of VHL may occur in
up to 20% of sporadic cRCC [4-6]. Although VHL pro-
moter methylation is not a feature of pRCC, methylation
of some TSGs, e.g. RASSF1A and SPINT2, occurs in both
cRCC and pRCC [7,8]. Relatively little is known about
how pathways of tumourigenesis in cRCC with and with-
out VHL inactivation compare, and, specifically, whether
epigenetic changes differ according to whether VHL is
inactivated or not. Epigenetic profiling to detect TSG pro-
moter methylation is an efficient strategy for investigating
tumourigenesis pathways in RCC. In contrast, with the
exception of VHL, the frequency of mutations in individ-
ual candidate TSGs in RCC is <15%
http:www.sanger.ac.uk/perl/genetics/CGP/cos
mic?action=byhist&amp;sn=kidney&amp;s=3, however,
we and others have identified at least 14 candidate TSGs
demonstrating tumour-specific promoter methylation in
>20% of RCC ([8,9], and references within). Furthermore,
recent technological developments have enabled analysis
of CpG methylation to be undertaken for many TSGs
simultaneously. In order to (a) gain a better understand-
ing of the frequency and nature of TSG methylation in
RCC and (b) compare the patterns of CpG methylation in
TSGs from papillary RCC and cRCC with and without
VHL inactivation, we analysed RCC samples using a high-
throughput CpG methylation analysis platform (Illumina
Goldengate Assay).
Methods
Tumour samples
Genomic DNA was extracted from primary renal cancers
and cell lines by standard methods, and stored at -80°C.
Three groups of renal cancers were investigated: (a) 29
cRCC from patients with von Hippel-Lindau disease, (b)
20 sporadic cRCC without evidence of somatic VHL muta-
tions or promoter methylation (details of mutation and
methylation analyses have been reported previously [4])
and (c) 13 papillary RCC. In addition, DNA samples from
normal kidney tissue (NKT) from patients without cancer
(n = 6, mean age 57 years, range from 23–79 years) and
24 kidney cancer cell lines were studied (786-0, 769P,
A498, A704, ACHN, Caki1, Caki2, CAL54, KTCL26,
KTCL140, NK2, RCC1, RCC4, RCC6, RCC11, RCC12,
RCC48, SKRC18, SKRC39, SKRC45, SKRC47, SKRC54,
UMRC2 and UMRC3). Ethical approval for collection of
clinical material was obtained from the South Birming-
ham Ethics Committee and relevant local ethics commit-
tees.
Methylation Studies
Illumina Goldengate Methylation Analysis
0.5 μg DNA samples were treated with sodium bisulphite
using the EZ DNA methylation Gold kit (Zymo), and the
bisulphite-treated DNA was applied to an Illumina bead
array [10] using the Illumina Goldengate Methylation
Cancer Panel http://www.illumina.com/
pages.ilmn?ID=193 (performed at the Wellcome Trust
Centre for Human Genetics, University of Oxford). Meth-
ylation results were analysed in a qualitative fashion (akin
to conventional methylation analysis using Methylation
Specific PCR (MSP)), such that a tumour was considered
to be positive for CpG methylation if the array detected
>25% methylation (this would correspond to complete
monoallelic CpG methylation in a tumour that contained
50% contaminating normal tissue). 84 genes were meth-
ylated (Mt > 0.25 in all 6 NKT but unmethylated (MtI ≤
0.25) in one or more primary tumours. To allow for nor-
mal variation, attention was focussed on 18 genes that
were methylated in 100% of NKT but <72% (lower 95%
CI) of primary renal tumours tested.
Validation of Illumina Goldengate methylation data
Prior to the current experiments, reproducibility was
established during alternative experiments using repli-
cates of several sample types including Universally Meth-
ylated Controls. These demonstrated high correlations
between repeated samples (r2 = 0.93–0.85). Three genes
with a total of four CpGs (EYA4_P508_F, EYA4_P794_F,
SOX17_P287_R, TNFRSF10C_E109_F) were analysed by
direct bisulphite sequencing in 6 RCC cell lines (RCC48,
CAL54, CAKI2, RCC1, RCC11, RCC12, 786P). 23 of 24
CpGs showed evidence of methylation by direct sequenc-
ing, and 22 of these were categorised as methylated by the
array analysis. One tumour with partial methylation by
direct sequencing at EYA4_P508_F was below the methyl-
ation threshold on the array analysis (methylation index,
MtI = 0.15). The remaining CpG, EYA4_P508_F in RCC
cell line 769-P, was unmethylated by both direct sequenc-Page 2 of 11
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correlation between the methylation results obtained by
the two methods and no evidence of a significant differ-
ence (McNemar test P = 1.0). In addition, inspection of
the broader sequence context of the particular CpGs tar-
geted by the Illumina array showed that the methylation
status of these individual CpGs was representative of the
methylation status of the surrounding CpGs.
Statistical and Bioinformatic Analysis
Kruskal-Wallis Test, log-likelihood G test, log-likelihood
G test for Goodness of Fit against Poisson Distribution,
and Pearson product-moment correlation coefficient
analyses were performed as appropriate. As the aim of the
research was merely to catalogue a list of plausible candi-
date tumour suppressor genes for RCC, without seeking to
prove their involvement or causality, the use of a Bonfer-
roni correction would have been unnecessarily restrictive,
especially given the large number of CpGs interrogated by
the Goldengate assay (n = 1505). P-values are therefore
given for indicative purposes only, with the acknowledge-
ment that a rigorous correction for multiple statistical test-
ing has not been applied.
Hierarchical cluster analysis was performed using Illu-
mina BeadStudio software http://www.illumina.com/
downloads/BEADSTUDIODataSheet.pdf with the Eucli-
dean algorithm (identical results were obtained with the
Manhattan algorithm) (see http://www.statsoft.com/text
book/stcluan.html) and used to create a heatmap with
associated dendrogram. Functional characteristics of
genes of interest were examined using Ingenuity Systems
software http://www.ingenuity.com.
Results
Epigenetic Profile of Human Renal Cancers and Cell Lines
The Illumina GoldenGate Methylation Cancer Panel I
array provides quantitative CpG methylation data at 1505
individual CpG dinucleotides associated with 807 human
genes. In order to profile patterns of RCC-specific candi-
date TSG methylation, we initially excluded 547 genes
from further analysis because (a) they were methylated in
Normal Kidney Tissue (NKT) (n = 338, this included X
chromosome genes), (b) were methylated only in cell
lines (n = 42), (c) were unmethylated in all samples stud-
ied (n = 101) or (d) a further 66 that fell into more than
one of the above three categories (genes could be in >1
category as most genes had >1 CpG interrogated). 260
genes were methylated in tumour but not in NKT, and
Euclidean cluster analysis was performed on these genes
(see later). The number of methylated genes per individ-
ual tumour ranged between 4 and 117. The distribution of
the number of methylated CpGs in individual tumours
differed from the expected Poisson distribution (p <
0.00001; log-likelihood G test) (see figure 1). This sug-
gested that the extent of methylation in individual
tumours was not randomly distributed, and that a subset
of RCC tumours might display CpG Island Methylator
Phenotype (CIMP+ tumours) (see Figures 1 and 2).
43 of 260 candidate non-imprinted tumour suppressor
genes were methylated in ≥ 20% (range 20–45%) of
tumours (these were designated "frequently methylated"
genes). These genes were analysed in detail, and are listed
in Additional file 1. In most cases (37/43 genes), methyl-
ation was more frequent in cell lines than primary
tumours, however for 6 genes this pattern was reversed
(ZNF215: 21% and 42% respectively, DAPK1: 4% and
39%, EPHA3 13% and 32%, SMARCB1: 8% and 27%,
EPS8 4% and 21% and MCM2: 0% and 21%).
18 genes were methylated in all six normal kidney tissue
samples but in <72% of renal tumours analysed: CARD15
(18% of tumours), HLA-DRA (24%), SPARC (34%), IL8
(35%), SEPT9 (39%), HLA-DPB1 (45%), TNFSF10
(47%), VAMP8 (50%), PRKCDBP (55%), HLA-DPA1
(56%), HDAC1 (58%), BTK (58%), S100A2 (60%), MPO
(61%), CRK (61%), CAPG (61%), NEU1 (69%), ELL
(71%). There was no consistent pattern in the frequency
of methylation loss in the different subtypes of renal
tumours (Figure 3).
Analysis of Methylation Patterns according to RCC 
Subtype
The overall distribution of methylation between the three
groups of tumours (VHL cRCC, sporadic wtVHL cRCC
and pRCC) was significantly different (p < 0.006; Kruskal-
Wallis Test). Thus, papillary RCCs demonstrated a geo-
metric mean of 62.5 tumour-specific methylated CpGs
per tumour, sporadic cRCCs had a geometric mean of
25.5 and VHL-associated cRCCs 20.9 methylated CpGs
per tumour (See Figure 1). Nevertheless, 15 genes (EYA4,
KCNK4, ZNF215, DAPK1, TMEFF2, SEPT5, SOX17,
PENK, CTSL, BMP4, HTR1B, COL1A2, FRZB, SMARCB1,
and CCNA1) were each methylated in >20% of the three
subtypes and did not show significant differences in
methylation frequency between tumour subtypes. Com-
parison of CpG methylation patterns in cRCC (VHL and
sporadic wtVHL) and pRCC demonstrated that (at a 1%
significance level using log-likelihood G-test) one gene
(CDH1) was more methylated in the cRCC (29% vs 0%; p
< 0.01) and 14 genes were more methylated in the papil-
lary RCC (RASSF1, SERPINE1, HOXA11, HOXC6, JAK3,
PDGFRB, MMP2, ITGB1, CREB1, MYOD1, GSTM2,
TNFRSF10C, SMARCA3 and COL1A1 (see Additional file
2). We considered that differences in methylation profiles
between different tumour types might be related to differ-
ing mechanisms of tumourigenesis or, potentially, to
ascertainment bias as most VHL tumours are detected pre-
symptomatically (via renal imaging surveillance pro-Page 3 of 11
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tumours. Indeed mean (±SD) tumour diameter in VHL
patients was 2.46 ± 0.56 compared to 6.3 ± 4.0 cm in
wtVHL-cRCC and 5.0 ± 3.6 in papillary RCC. However,
although, on average, pRCC were smaller than wtVHL-
cRCC, tumour-specific CpG methylation was generally
higher in pRCC (see above) and 12 genes were more fre-
quently methylated in pRCC than in wtVHL-cRCC
(SERPINE1, HOXC6, HOXA11, JAK3, ITGB1, PDGFRB,
RARB, GSTM2, MYOD1, SMARCA3(HTLF), GABRB3 and
TGFB2), whereas only 5 genes were more frequently
methylated in wtVHL-cRCC than pRCC (TWIST1, TIAM1,
DCC, CDH1 and PTGS2) (all at p ≤ 0.025 (see Additional
file 2)), There was a significantly positive correlation
(Pearson product-moment correlation coefficient; p <
0.05) between tumour size and gene methylation in only
three genes with differential methylation between tumour
types (PDGFRB, TIAM1 and GSTM2), suggesting that in
most cases the observed differential methylation is related
to different tumour histologies rather than to tumour size.
Comparison of methylation patterns in VHL cRCC and
sporadic wtVHL cRCC demonstrated that 11 frequently
methylated genes (i.e. genes methylated in > 20% of at
least one tumour type) were significantly (p < 0.025)
more frequently methylated in wtVHL sporadic RCC than
in VHL RCC (RASSF1, TWIST1 PITX2, CDH13, HS3ST2,
TAL1, WT1, MMP2, DCC, ICA1 and TUSC3:(all p < 0.025;
log-likelihood G-test; see Additional file 2). One fre-
quently methylated gene was significantly more fre-
quently methylated in VHL-associated cRCC than in
wtVHL sporadic cRCC: GABRB3 (48% vs 20%; log-likeli-
hood G-test, p < 0.05; a less stringent p-value was used
due to the lower overall frequency of methylation in the
VHL subgroup). For genes more methylated in wtVHL
than VHL-RCC, RASSF1, PITX2, CDH13, HS3ST2, TAL1,
TUSC3 and DCC were at least as frequently methylated in
tumours < 5 cm as those ≥ 5 cm. Euclidean cluster analysis
for 260 genes showing tumour-specific methylation was
performed (this analysis used quantitative methylation
index data) and there was significant evidence of cluster-
ing of tumour types (comparing VHL and non-VHL
tumours (Fisher exact P = 0.00042) and using all three
types χ2 = 13.3, df = 2, P = 0.0013) (see Figure 2)
To determine if differential CpG methylation patterns in
RCC might relate to preferential targeting of specific sig-
nalling pathways, the Ingenuity functional annotation
Distribution of the number of genes found to be >25% methylated in each tumour, according to histological typeFigure 1
Distribution of the number of genes found to be >25% methylated in each tumour, according to histological 
type. Poisson probabilities are based on the geometric mean of the total observed data (i.e. λ = 27.609) Geometric mean 
number of genes methylated for each tumour type is indicated by coloured circles on the x-axis.
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Molecular Cancer 2009, 8:31 http://www.molecular-cancer.com/content/8/1/31pathway was utilised. 8/14 genes that were significantly
more methylated in pRCC than cRCC were represented in
a network with links to TGFβ and ERK/Akt pathways (see
Figure 4). The link to these pathways was more pro-
nounced (9/12) for those 12 genes that were more fre-
quently methylated in pRCC than in wtVHL-cRCC (see
Figure 5 (see figure 6 for key to nodal shape in figures 4
and 5). The 18 genes that were methylated in all NKT sam-
ples but <72% of renal tumours did not demonstrate a sig-
nificant association with a particular pathway.
Discussion
High throughput methylation profiling platforms such as
the Illumina Goldengate assay enable extensive methyla-
tion profiling of human tumours for a large number of
genes. Although many of the genes represented in the
assay have previously been reported as methylated in
human cancers, most (33/42) of the candidate tumour
suppressor genes that were methylated in ≥ 20% of all pri-
mary RCC tested had not previously been reported to be
methylated in RCC (HTR1B, CALCA, IGFBP2, SOX17,
COL1A2, BMP4, HS3ST2, FRZB, TAL1, MCM2, KCNK4,
HOXC6, PITX2, SEPT5, IRF7, CCNA1, HOXA11, TERT,
TMEFF2, EPHA3, PGF, MYOD1, MMP2, TNFRSF10C,
PENK, EYA4, MYLK, IRAK3, ZNF215, SMARCB1,
TWIST1, SCGB3A1, and IGFBP7). Thus our analysis sug-
gests a large number of potential epigenetic biomarkers
and/or TSGs for RCC. In addition, several of these genes
have not previously been reported as methylated in any
type of cancer (KCNK4, SEPT5, PENK, BMP4, TAL1, PGF,
SMARCB1 (INI1), FRZB (SFRP3), IRAK3 and MCM2).
Detection of methylated CpGs in urine has been investi-
gated as a potential screening tool for RCC and other uri-
nary tract neoplasms (reviewed in ref 11). To date, no
single gene is known to be hypermethylated in all RCCs,
and so successful application of promoter methylation
assays as biomarkers will necessitate the study of multiple
loci. Ideally the combination of loci chosen for such a
screening strategy would cover all types of RCC. Such a
panel might include genes that are (a) methylated in all
types of RCC and (b) preferentially methylated in a partic-
ular subtype of RCC, as such a combination could provide
a basis for minimally-invasive screening for diagnosis,
prognostication and therapeutic targeting. The potential
for such a strategy is demonstrated by the results of Eucli-
dean cluster analysis that grouped most tumours into
groups consistent with their histopathology/VHL status.
We found evidence that a small number of RCC har-
boured more methylated CpGs than would be expected
by chance. This provides evidence for a "CpG island meth-
ylator phenotype" (CIMP+) in a subset of RCC. CIMP+
tumours were not specific to any subgroup of RCC. The
concept of a CIMP+ phenotype was developed from stud-
ies of colorectal cancer and remained controversial until
Heat map showing gene (n = 260) methylation patterns in 62 primary RCCFigure 2
Heat map showing gene (n = 260) methylation pat-
terns in 62 primary RCC. Euclidean cluster analysis dem-
onstrates preferential grouping of VHL tumours (VHL 01 – 
29) versus non-VHL sporadic cRCC (CC Spor 01 – 21) and 
papillary tumours (papillary 01 – 13). Tumours are shown on 
the x-axis. CpG sites from 260 candidate genes are shown on 
the y-axis. Methylation is colour coded from 0% (green) to 
100% (red)Page 5 of 11
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to defining putative CIMP-related markers, Weisenberger
et al (a) provided evidence for CIMP+ colorectal cancer
and (b) demonstrated that CIMP+ sporadic colorectal
cancers were associated with the presence of a BRAF muta-
tion and microsatellite instability (from MLH1 promoter
methylation) (12). Although CIMP has been described in
a range of other tumour types (including head and neck
squamous cell carcinoma, bladder cancer, non-small cell
lung cancer and malignant pleural mesothelioma) [13],
evidence for a CIMP in RCC has not been reported previ-
ously. However, we note that Dulaimi et al [14] reported
that a subset of RCC (~3%) were methylated for at least
five out of the ten genes studied. Identification of further
CIMP+ RCCs will provide a basis for determining whether
tumours with extensive CpG methylation have distinct
clinical characteristics and whether a subset of genes are
methylated only in CIMP+ phenotype tumours. The
molecular causes of CIMP are not well-understood and
identification of CIMP+ tumours will facilitate further
studies to investigate the molecular basis of this pheno-
type [15].
We were interested to compare the methylation profiles of
cRCC and papillary RCC, as little information is available
on this topic. Several genes were significantly (p < 0.025)
more frequently methylated in papillary than in cRCC
(and similarly methylated in both cRCC subtypes). These
loci could prove to be useful candidate biomarkers for
papillary RCC and might give insights into differing
mechanisms of tumourigenesis in papillary and cRCC,
thereby enable focusing of targeted therapeutic drugs in
different disease sub-types. Recently, Matsuda et al [16]
undertook high resolution array CGH studies in sporadic
RCC and reported that whereas cRCC was characterized
by frequent 3p loss and 5q gain, papillary RCC demon-
strated frequent gains on chromosomes 2, 7, and 12; addi-
tionally, loss on 1q, 9, and 11q was unique to papillary
RCC. However none of the loci preferentially methylated
in papillary RCC mapped to 1q, 9 or 11q; and RARB,
although preferentially methylated in papillary RCC,
maps to 3p24. Thus loci with high frequencies of CpG
methylation may occur in regions with a low frequency of
allele loss. It is noteworthy that both HOXA11 and
HOXC6 were preferentially methylated in papillary RCC.
Genes that were methylated in all normal kidney tumour samples (N = 6) but methylated in <72% of renal tumours analysed: comparison of frequency of methylation in diff rent tumour typFigure 3
Genes that were methylated in all normal kidney tumour samples (N = 6) but methylated in <72% of renal 
tumours analysed: comparison of frequency of methylation in different tumour types.Page 6 of 11
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Molecular Cancer 2009, 8:31 http://www.molecular-cancer.com/content/8/1/31However, although evidence for preferential methylation
of genes within a specific chromosome region has been
reported in colon cancer [17], HOXA11 and HOXC6 map
to 7p15-p14 and 12q13.3 respectively and so their prefer-
ential involvement in papillary RCC presumably reflects
their related functions rather than their cytogenetic loca-
tion. Three genes, CDH1, PTGS2 and TWIST1 were specif-
ically methylated in cRCC (both p < 0.025 compared to
papillary RCC). Germline mutations in CDH1 and
TWIST1 may be associated with inherited cancer suscepti-
bility. Thus, CDH1 mutations cause familial diffuse type
gastric cancer [18] and the TWIST1 transcription factor is
mutated in Saethre-Chotzen syndrome, which is charac-
terised by developmental defects (craniosynostosis and
Most significant gene networks for genes more methylated in papillary RCC than clear cell RCCFigure 4
Most significant gene networks for genes more methylated in papillary RCC than clear cell RCC. Genes in 
unfilled nodes were not identified as specifically methylated in tumours (TGF-β, AKT, PDGFB) or were not represented on the 
array (ITGA8, ITGA10, ITGA11, PEBP4, ERK, SLC12A4, JNK, ITGB1BP2, CDO1, NCK1, NLK, PI3K, CNN2, FSD1, SLC7A8, 
ELOVL2, FXYD5, PDGFD and PDAP1. The computationally generated networks were derived using the Ingenuity package 
http://www.ingenuity.com. (see Figure 6 for key to nodal shape).Page 7 of 11
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with an increased risk of breast cancer [19]. PTGS2
(COX2) encodes prostaglandin-endoperoxide synthase 2,
and recently Costa et al [20] also reported that PTGS2
methylation levels were significantly higher in cRCC than
papillary RCC. Thus these three genes might prove to be
useful epigenetic biomarkers for the diagnosis of cRCC
(e.g. in needle aspirates). We note that many of the genes
that were preferentially methylated in pRCC could be
linked in to TGF-β/ERK/Akt pathways. Although the role
of TGF-β-related pathways have not been investigated in
pRCC, we note that TFE3 may regulate TGF-β signalling
[21] and that a subgroup of pRCC are charcaterised by
chromosomal translocations involving TFE3 [22].
Most significant gene networks for genes more methylated in papillary RCC than non-VHL sporadic cRCCFigure 5
Most significant gene networks for genes more methylated in papillary RCC than non-VHL sporadic cRCC. 
Genes in unfilled nodes were not identified as specifically methylated in tumours (AKT), were not represented on the array 
(SMAD3/SMAD4, RIL3, LRG1, TGFBR, FERMT1, P38MAPK, MYBPH, RNA polymerase II, insulin, PI3K, ERK, Ap1, SLC12A7, 
PDGFB, Pkc(s), CDO1, CNN2, VAPB, PDGFD) or were methylated in tumours but with no frequency difference between 
tumour types (CCNA1). The computationally generated networks were derived using the Ingenuity package http://www.inge-
nuity.com (see Figure 6 for key to nodal shape).
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Molecular Cancer 2009, 8:31 http://www.molecular-cancer.com/content/8/1/31Although most sporadic cRCC have evidence of VHL inac-
tivation, little is known about whether VHL-inactivated
and VHL-wt RCC have differing or similar (for VHL-inde-
pendent events) mechanisms of tumourigenesis. Also,
there is little information on the somatic changes (other
than VHL inactivation) associated with RCC from VHL
patients. To our knowledge, this is the first investigation
of epigenetic alterations in VHL-null and VHL-wt RCC.
We found that a number of loci, including RASSF1, PITX2,
CDH13, HS3ST2, TWIST1, TAL1, TUSC3 and DCC were
significantly more frequently methylated in VHL-wt spo-
radic RCC than in VHL RCC. It might be hypothesised
that genes whose functions overlap with that of VHL-
related pathways might be preferentially inactivated in
RCC without VHL inactivation. Therefore it is interesting
that both VHL and RASSF1A downregulate Cyclin D1 [23-
25]. However, although CDH1 expression is downregu-
lated by VHL inactivation, and DAPK1 by RASSF1A inac-
tivation, CDH1 and DAPK1 methylation frequencies were
similar in wtVHL sporadic RCC and VHL RCC. Also we
note that all of the genes that were preferentially methyl-
ated in wtVHL sporadic RCC mapped to different chro-
mosomal locations, and there was no evidence that a
specific chromosomal domain was more frequently meth-
ylated in a specific tumour type. 5 genes that were more
frequently methylated in sporadic wtVHL-cRCC than VHL
RCC were included in a network that related to ERK/Akt
signalling. Both the Raf-extracellular signal-regulated pro-
tein kinase (Erk)1/2 and Akt-mTOR pathways have been
implicated in the pathogenesis of familial and sporadic
RCC [26,27]. VHL-inactivation may be associated with
activation of the epidermal growth factor receptor/phos-
phatidylinositol-3-OH kinase/protein kinase B (AKT)/
IkappaB-kinase alpha/NF-kappaB signalling cascade [28],
and so RCC without VHL inactivation may be predis-
posed to dysregulate these key signalling pathways by
preferential methylation of other regulators. Although it
might be predicted that the pathways of tumourigenesis
in VHL mutated sporadic clear cell RCC will be similar to
those in RCC from VHL patients, further studies (using
the methods utilised in this study) are indicated to inves-
tigate this point.
It is generally thought that CpG island methylation in
cancer is non-random, and many genes that are frequently
methylated have been shown to have a tumour suppressor
or DNA repair function. TSGs may be targeted by epige-
netic silencing and/or inactivating mutations during
tumourigenesis. However, whereas the repertoire of inac-
tivating mutations in a typical tumour suppressor gene is
extensive, patterns of CpG island methylation causing epi-
genetic silencing are much more restricted and hence are
easier to detect. The relative frequency of CpG island
methylation and inactivation mutations for individual
TSGs is variable. For example, although VHL is primarily
inactivated by somatic mutations (promoter methylation
occurs in ~15% of sporadic cRCC), inactivation of the
RASSF1A TSG in RCC (and in other tumour types) most
commonly results from promoter methylation, whilst
intragenic mutations are rare. According to the Catalogue
of Somatic Mutations in Cancer (COSMIC; http://
www.sanger.ac.uk/perl/genetics/CGP/cosmic) only three
genes are mutated in >5% of RCC tested (VHL = 42%,
CDKN2A = 12% and KIT = 8%). Thus, with the exception
of VHL, epigenetic biomarkers are likely to provide a bet-
ter approach for novel prognostic and diagnostic strate-
gies than genetic markers [29]. This is substantiated by the
observation that, of the 43 genes that were methylated in
>20% of RCC tested, RCC mutation analysis data is avail-
able for 21, of which none are subject to somatic muta-
tions in RCC. Further characterisation of the genes and
pathways that are epigenetically altered in RCC of differ-
ent subtypes may thus lead to the development of novel
minimally-invasive diagnostic and prognostic tools for
kidney cancer, and, in the longer term, may enable more
focused treatments for individual tumours.
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